Nektar Therapeutics
Last updated September 27, 2026
Organization details
- Legal name
- Nektar Therapeutics
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- NKTR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000906709
Board of directors
-
Diana Brainard · DirectorSince 2023
-
Howard W. Robin · Director · President & CEOSince 2023
-
Jeffrey Robert Ajer · DirectorSince 2023
-
Myriam Curet · DirectorSince 2023
-
R. Scott Greer · DirectorSince 2023
-
Robert Chess · DirectorSince 2023
-
Roy A. Whitfield · DirectorSince 2023
Chief executives
Howard W. Robin
· President & CEO
Dates unknown
Board connections
4 of this board's directors also sit on 6 other boards.
- via Myriam Curet
- via Diana Brainard
- via Myriam Curet
- via Myriam Curet
- via Robert Chess
- via Jeffrey Robert Ajer
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $2,433,286
- 16 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2026 | Jeffrey Robert Ajer Director | Grant or award | +2,000 | — | — |
| Sep 23, 2026 | Diana Brainard Director | Grant or award | +2,000 | — | — |
| Sep 23, 2026 | Robert Chess Director | Grant or award | +2,000 | — | — |
| Sep 23, 2026 | R. Scott Greer Director | Grant or award | +2,000 | — | — |
| Sep 23, 2026 | Roy A. Whitfield Director | Grant or award | +2,000 | — | — |
| Aug 18, 2026 | Howard W. Robin Director, Officer (President & CEO) | Open-market sale | −418 | $71.98 | $30,088 |
| Aug 18, 2026 | Zalevsky Jonathan Officer (Chief R&D Officer) | Open-market sale | −186 | $71.98 | $13,388 |
| Jun 30, 2026 | Zalevsky Jonathan Officer (Chief R&D Officer) | Open-market sale | −5,681 | $70.00 | $397,670 |
| Jun 17, 2026 | Howard W. Robin Director, Officer (President & CEO) | Open-market sale | −5,500 | $60.81 | $334,455 |
| Jun 17, 2026 | Howard W. Robin Director, Officer (President & CEO) | Open-market sale | −4,500 | $61.65 | $277,425 |
| Jun 16, 2026 | Howard W. Robin Director, Officer (President & CEO) | Open-market sale | −5,303 | $59.97 | $318,021 |
| Jun 16, 2026 | Howard W. Robin Director, Officer (President & CEO) | Open-market sale | −4,697 | $60.71 | $285,155 |
| Jun 15, 2026 | Zalevsky Jonathan Officer (Chief R&D Officer) | Open-market sale | −5,538 | $60.71 | $336,212 |
| May 19, 2026 | Zalevsky Jonathan Officer (Chief R&D Officer) | Open-market sale | −199 | $65.51 | $13,036 |
| May 19, 2026 | Howard W. Robin Director, Officer (President & CEO) | Open-market sale | −444 | $65.51 | $29,086 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.